Archive for the ‘Artificial Intelligence’ Category

Spending on Artificial Intelligence Solutions Will Double in the United States by 2025, According to a New IDC Spending Guide – Business Wire

NEEDHAM, Mass.--(BUSINESS WIRE)--Spending on artificial intelligence in the United States will grow to $120 billion by 2025, representing a compound annual growth rate (CAGR) of 26.0% over the 2021-2025 forecast period. Moreover, all 19 U.S. industries profiled in the latest Worldwide Artificial Intelligence Spending Guide from International Data Corporation (IDC) are forecast to deliver AI spending growth of 20% or more. The U.S. also accounts for more than half of all AI spending worldwide.

Retail will remain the largest U.S. industry for AI spending throughout the forecast while Banking will be the second largest industry. Together, these two industries will represent nearly 28% of all AI spending in the United States in 2025 and will account for nearly $20 billion of the amount added to the U.S. total over the forecast. The U.S. industries that will see the fastest growth in AI spending will be Professional Services, Media, and Securities and Investment Services, all of which will have CAGRs greater than 30%.

Within Retail, the AI use cases that will receive the most investment will be Augmented Customer Service Agents, and Expert Shopping Advisors & Product Recommendations. These two use cases encourage and assist increased spending by retail customers and account for nearly 40 percent of AI spending in the industry. The shift to online shopping contributes considerably to the adoption of AI within retail. AI spending in the Banking industry will be spread across several different functional areas, including customer service (Program Advisors and Recommendation Systems), operations (Fraud Analysis and Investigation), and security (Augmented Threat Intelligence and Prevention Systems).

Among the 30 AI use cases included in the Spending Guide, two will remain the largest in terms of total spending throughout the forecast Augmented Customer Service Agents and Sales Process Recommendation and Augmentation. Together, these two use cases will account for more than 20% of all AI spending in the U.S. in 2025. In terms of growth, two AI use cases (Public Safety and Emergency Response and Augmented Claims Processing) will have five-year CAGRs greater than 30% while a third use case (IT Optimization) will ride a CAGR of 29.7% to become the third largest AI use case in 2025.

"The greatest potential benefit for the use of AI remains its use in developing new business, and building new business models," said Mike Glennon, senior research manager with IDC's Customer Insights & Analysis team. "However, existing businesses are hesitant to embrace this potential, leaving the greatest opportunities to new market entrants that have no fear of change and can adapt easily to new ways of conducting business. The future for business is AI and those companies that can seize this opportunity could easily become the new giants."

The Worldwide Artificial Intelligence Spending Guide sizes spending for technologies that analyze, organize, access, and provide advisory services based on a range of unstructured information. The Spending Guide quantifies the AI opportunity by providing data for 30 use cases across 19 industries in nine regions and 32 countries. Data is also available for the related hardware, software, and services categories.

Taxonomy Note: The IDC Worldwide Artificial Intelligence Spending Guide uses a precise definition of what constitutes an AI Application in which the application must have an AI component that is crucial to the application without this AI component the application will not function. This distinction enables the Spending Guide to focus on those software applications that are strongly AI Centric. In comparison, the IDC Worldwide Semiannual Artificial Intelligence Tracker uses a broad definition of AI Applications that includes applications where the AI component is non-centric, or not fundamental, to the application. This enables the inclusion of vendors that have incorporated AI capabilities into their software, but the applications are not exclusively used for AI functions only. In other words, the application will function without the inclusion of the AI component.

About IDC Spending GuidesIDC's Spending Guides provide a granular view of key technology markets from a regional, vertical industry, use case, buyer, and technology perspective. The spending guides are delivered via pivot table format or custom query tool, allowing the user to easily extract meaningful information about each market by viewing data trends and relationships.

Click here to learn about IDC's full suite of data products and how you can leverage them to grow your business.

About IDCInternational Data Corporation (IDC) is the premier global provider of market intelligence, advisory services, and events for the information technology, telecommunications, and consumer technology markets. With more than 1,200 analysts worldwide, IDC offers global, regional, and local expertise on technology, IT benchmarking and sourcing, and industry opportunities and trends in over 110 countries. IDC's analysis and insight helps IT professionals, business executives, and the investment community to make fact-based technology decisions and to achieve their key business objectives. Founded in 1964, IDC is a wholly owned subsidiary of International Data Group (IDG), the world's leading tech media, data, and marketing services company. To learn more about IDC, please visit http://www.idc.com. Follow IDC on Twitter at @IDC and LinkedIn. Subscribe to the IDC Blog for industry news and insights.

Read more:
Spending on Artificial Intelligence Solutions Will Double in the United States by 2025, According to a New IDC Spending Guide - Business Wire

Aster launches artificial intelligence lab in collaboration with Bengaluru IISc – The Indian Express

Bengalurus Aster CMI Hospital, in association with the Indian Institute of Science (IISc), launched an artificial intelligence (AI) lab on Friday. The Aster-AI lab is a collaborative lab, set up with the aim to build cutting-edge AI products in the healthcare domain and bridge the gap between clinical medicine and technology by training healthcare professionals in AI.

Speaking on how technology is transforming the healthcare system in India, Dr Azad Moopen, founder chairman and managing director of the Aster DM Healthcare conglomerate, said, With the use of AI, doctors and medical providers will now be able to deliver more accurate diagnosis in the fastest possible time, which can aid the treatment journey. Also, AI would be a big leap towards predictive and proactive data analytics, which will improve preventive care recommendations for patients. We are really glad to partner with IISc, which will open doors for healthcare professionals to undertake research and better utilize AI tools to understand their patients disease patterns and improve treatment outcomes significantly.

Commenting on the collaboration, Dr Lokesh B, a neurologist at the hospital, said, This lab will be hosted at Aster CMI to enable faster translation into the clinical care system. This collaboration is only a start; future scope includes exchange of personnel as well as joint workshops for increased cooperation in making AI in medicine more effective both for clinicians as well as patients. This is the first collaborative lab in the clinical environment with an aim to perform impactful as well as translatable research work in the space of AI in medicine.

Phaneendra K Yalavarthy, professor of medical imaging at the IISc, has been instrumental in setting up the lab by providing computational infrastructure and expertise. Yalavarthy said, Artificial intelligence-powered medical technologies have been rapidly evolving and have become powerful adjunct tools in clinical practice. The broad spectrum of digital medicine, especially to enable the 4P model of medicine (predictive, preventive, personalized, and participatory) involves natural collaboration between academic institutions and medical institutions. This artificial intelligence lab is a collaborative effort to develop these AI technologies in the hospital settings so that the translation to the clinic will be seamless. The initial focus of this collaborative lab will be in neurology and its scope will later be expanded to other clinical specialities.

The hospital will be working with Yalavarthy and his team on the development of deep-learning methods for automated tracking and segmentation of nerves in ultrasound images. Dr Sriram Ganapathy, associate professor of electrical engineering, has been collaborating on automatic acute stroke symptom detection using mobile health technologies and also on audio analytics in neurological disorders. These initial projects have a direct impact on the current clinical practice in neurosciences. The problem-solving requires deep technical and clinical knowledge, which the Aster-AI lab aims to bring together.

Excerpt from:
Aster launches artificial intelligence lab in collaboration with Bengaluru IISc - The Indian Express

Media Partnership – Discrimination and surveillance: Can the EU Artificial Intelligence Act fix injustice? – EURACTIV

Listen to the full event here:

The EU is taking a bold step in its attempt to regulate artificial intelligence a technology that is increasingly used in many areas of public life. Unfortunately, artificial intelligence systems also exacerbate existing injustices and create new harms for people who already suffer from racial discrimination and systemic injustice. The EUs Artificial Intelligence Act brings a unique opportunity to correct and prevent those harms, and to give people ways to seek redress.

The Open Society European Policy Institute and European Digital Rights (EDRi) invite you to rewatch us on a deep dive with EU policy-makers, academic and civil society experts. The virtual conference explored how the Artificial Intelligence Act can be a positive force in Europe towards protecting peoples human rights and delivering social justice.

ORGANISED BY: The Open Society European Policy Institute and European Digital Rights (EDRi)

MEDIA PARTNER: EURACTIV

>>Clickherefor more information about the event.

>>Clickhereto check outour upcoming event

Read the original post:
Media Partnership - Discrimination and surveillance: Can the EU Artificial Intelligence Act fix injustice? - EURACTIV

Newly unveiled Qassim Science Center hosts its first event series, The Robotic and Artificial Intelligence Festival – PR Newswire

Most festival visitors witnessed inventions for the first time, challenging guests to rethink the way we may one day go about our daily lives. Festival seekers were greeted by a host robot who encouraged fluid conversation in Arabic, speaking on a variety of topics from tourism, health and pop culture. Families, couples, and school groups from around the region of Qassim were encouraged to explore and immerse themselves throughout the 600 square meter event space, broken up into 3 experience zones:

In addition to the 3 zones, the festival offered a series of half-hour workshops relating to various technologies, beyond those featured in the zones, from ioT, blockchain, and quantum computing. The venue also provided groups with a leisure area where food trucks, pop-up coffee shops and lounge space could accommodate festival goers.

The festival was curated and organized by Knowliom, a Riyadh based agency that specializes in museum management, edutainment and informal educational programming. Adil Khan, Digital Fabrication Expert at Knowliom and Lead Festival Curator said, "It was essential to our team that we provide an awe inspiring guest experience while at the same time showcasing how real and accessible these inventions are and how they may improve our quality of life. Furthermore, Most festivals and gatherings of this caliber are hosted in the capital city of Riyadh, therefore it was an honor to bring cutting edge technology inventions and hands-on experiences into a relatively remote region of Saudi Arabia."

About Knowliom

Leading the way in informal learning experiences throughout the Kingdom of Saudi Arabia, Knowliom is a privately held company and member of All Group, a conglomerate of event-centric companies dedicated to enhancing the quality of life and elevating entertainment experiences around the region. Knowliom is an agency based in Riyadh, that provides museum operation solutions, edutainment as well as learning and cultural based programming to its clients. Working on a variety of projects, from art exhibitions, science museums to heritage festivals, Knowliom's team blends together its deep understanding of the local market with its broad perspective of international learning standards to deliver fun, interactive and meaningful experiences to festival, museum and programming guests.

For more information, please visit http://www.knowliom.comor contact [emailprotected]for direct inquiries.

SOURCE Knowliom

Originally posted here:
Newly unveiled Qassim Science Center hosts its first event series, The Robotic and Artificial Intelligence Festival - PR Newswire

Artificial Intelligence (AI) in Drug Discovery Industry Share, Size, Emerging Technologies, Future Trends, Competitive Analysis, and CAGR of 41.0% By…

A recently announced report titled Global Artificial Intelligence (AI) in Drug Discovery Market Size, Share, Growth, Industry Trends and Forecast 2028 by Data Bridge Market Research aims to deliver a detailed investigation of all necessary data related to the global market. Artificial Intelligence (AI) in Drug Discovery Industry Research Report is an in-depth and deep Research on the present condition of the Artificial Intelligence (AI) in Drug Discovery industry in the global market. Furthermore, this Report presents a detailed overview; cost structure, size, revenue, growth, share, dynamics, competitive analysis, Companies and Artificial Intelligence (AI) in Drug Discovery strategy & statistics analysis. This Report is segmented on basis of product type, end-user, application and geographical regions. These trends are anticipated for the market during the forecast period from 2022 to 2028.

Download Exclusive Sample Report (To Know More Insights on Market Size, Share, Growth, Trends, and Company Profile Analysis) @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-artificial-intelligence-ai-in-drug-discovery-market

Market Analysis and Size

Artificial Intelligence (AI) is described as a machine that uses advanced technologies to execute activities related to the human mind. Medicine discovery researchs main goal is to find drugs that can help in the prevention or treatment of specific diseases. The challenges of examining, gathering, and applying data to solve challenging medical problems in the pharmaceutical sector fuelled the demand for artificial intelligence (AI) in drug discovery market.

Data Bridge Market Research analyses that the Artificial Intelligence (Ai) In Drug Discovery Market is expected to reach the value of USD 7,818.93 million by 2029, at a CAGR of 41.0% during the forecast period. Artificial intelligences expanded applications in a variety of areas of medicine discovery, including polypharmacology, chemical synthesis, drug screening, drug design, and drug repurposing, are expected to significantly boost market growth.

Report Highlights:

The report firstly introduced Artificial Intelligence (AI) in Drug Discovery basics: definitions, classifications, applications and market overview; product specifications; manufacturing processes; cost structures, raw materials and so on. Then it analyzed the worlds main region market conditions, including the product price, profit, capacity, production, supply, demand and Artificial Intelligence (AI) in Drug Discovery market growth rate and forecast etc. In the end, the report introduced new project SWOT analysis, investment feasibility analysis, and investment return analysis.

Artificial Intelligence (AI) in Drug Discovery Market Dynamics

Drivers

Strategic collaborations and partnerships

The increasing number of cross-industry collaborations and partnerships will act as major driver influencing the markets growth rate.

Reduction in total time involved in drug discovery process

Competitive Analysis

Complete Report Details with Table of Content and Figures https://www.databridgemarketresearch.com/toc/?dbmr=global-artificial-intelligence-ai-in-drug-discovery-market

With an extensive SWOT analysis, the Data Bridge Market Research study presents the strengths, weaknesses, growth prospects and challenges of each player. The report also includes important data including the sales strategy, pricing strategy, and marketing strategy adopted by these players in the Artificial Intelligence (AI) in Drug Discovery market.

Artificial Intelligence (AI) in Drug Discovery Market: Segmentation

By Offering (Software, Services),

By Technology (Machine Learning, Other Technologies)

By Drug Type (Small Molecule, Large Molecules)

By Application (Immuno-Oncology, Neurodegenerative Diseases, Cardiovascular Disease, Metabolic Diseases, Other Applications)

By End-User (Pharmaceutical & Biotechnology Companies, Contract Research Organizations, Research Centres and Academic & Government Institutes)

Critical Questions Answered in the Report

COVID-19 Impact on Artificial Intelligence (AI) in Drug Discovery Market

The COVID-19 outbreak had a beneficial impact on the expansion of artificial intelligence in drug discovery industry due to its widespread use by various organization for the identification as well as screening of existing medicines used in the treatment of COVID-19. Artificial intelligence (AI) has been shown to be useful in detecting active chemicals for the prevention of SARS-CoV, HIV, SARS-CoV-2, influenza virus, and others. During the pandemic, economies all over the world relied on artificial intelligence-based medication discovery rather than traditional vaccine detection processes, which take years to create and are equally expensive, contributing to the growth of artificial intelligence (AI) in drug discovery market.

To Gain More Insights into the Artificial Intelligence (AI) in Drug Discovery Market Analysis, Browse Summary of the Research [emailprotected] https://www.databridgemarketresearch.com/reports/global-artificial-intelligence-ai-in-drug-discovery-market

Global Artificial Intelligence (AI) in Drug Discovery Market Scope

The artificial intelligence (AI) in drug discovery market is segmented on the basis of offering, technology, drug type, application and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Offering

Based on offering, artificial intelligence (AI) in drug discovery market is segmented intosoftwareand services.

Technology

On the basis of technology, artificial intelligence (AI) in drug discovery market is segmented intomachine learningand other technologies. Machine learning has been further segmented into deep learning, supervised learning, reinforcement learning, unsupervised learning and other machine learning technologies.

Drug Type

Based on drug type, artificial intelligence (AI) in drug discovery market is segmented into small molecule and large molecules.

Application

On the basis of application, artificial intelligence (AI) in drug discovery market is segmented into immuno-oncology, neurodegenerative diseases, cardiovascular disease, metabolic diseases and other applications.

End-User

Why Data Bridge Market Research?

Thanks for reading this article, you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

Contact Us:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

E-Mail:[emailprotected]

Excerpt from:
Artificial Intelligence (AI) in Drug Discovery Industry Share, Size, Emerging Technologies, Future Trends, Competitive Analysis, and CAGR of 41.0% By...